Randomized, Double-Blind, Placebo-Controlled, Parallel-Cohort Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Once-Daily Application of Topical VDA-1102 Ointment for 28 Days in Subjects With Actinic Keratosis
Phase of Trial: Phase II
Latest Information Update: 11 May 2017
At a glance
- Drugs VDA 1102 (Primary)
- Indications Actinic keratosis
- Focus Therapeutic Use
- Sponsors VidacPharma
- 08 May 2017 Status changed from recruiting to completed.
- 20 Oct 2016 Status changed from not yet recruiting to recruiting.
- 29 Jun 2016 Status changed from planning to not yet recruiting, according to a Vidac Pharma media release.